Comparative Study of Thiazolidinediones in Clinical Use

摘要

Iype 2 diabetes is a disease state associated with various metabolic abnormalities, including dyslipidemia and hypertension, which increase cardiovascular risks Consequently, the goals for management of type 2 diabetes have evolved in recent years to include other measures aside from only glycemic control (eg, blood pressure, lipid levels) The thiazolidinediones (IZDs) play a fundamental role in the management of type 2 diabetes These agents provide effective, lasting glycemic control and may exert beneficial effects on atherogenic processes Ihis retrospective database analysis was designed to evaluate the effects of rosiglitazone, pioglita-zone, and troglitazone in the clinical practice setting We conclude that the 3 TZDs are equally effective in maintaining glycemic control and have similar incidences of weight gain and edema in the long term Ihese agents may produce subtle variations in lipid profiles as described in short-teim studies, but this is the first study that addresses the lipid data more than 1 year after treatment Some subtle variations in blood pressure effects were noted demonstrating the need for fewer antihypeitensive medications for patients taking rosiglitazone to achieve the same blood pressure goals as patients taking pioglitazone or troglitazone